Open AccessBromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma
Author(s) -
Altaf A. Dar,
Vladimir Bezrookove,
Mehdi Nosrati,
Ryan J. Ice,
John M Patino,
Edith M. Vaquero,
Brian M. Parrett,
Stanley P. L. Leong,
Kevin B. Kim,
Robert J. Debs,
Liliana Soroceanu,
James R. Miller,
PierreYves Desprez,
James E. Cleaver,
Nathan Salomonis,
Sean D. McAllister,
Mohammed KashaniSabet
Publication year - 2022
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2206824119
Subject(s) - melanoma , cancer research , neuroblastoma ras viral oncogene homolog , targeted therapy , mek inhibitor , medicine , bromodomain , combination therapy , dabrafenib , vemurafenib , mapk/erk pathway , kinase , pharmacology , biology , cancer , epigenetics , gene , kras , genetics , colorectal cancer , metastatic melanoma